NCT02859259

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Relative Bioavailability Study of BMS-626529 Administered as Prodrug BMS-663068 From 150-mg Low-dose Extended-release Tablets Compared to 600-mg Reference Extended-release Tablet in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068

Conditions

• Infection, Human Immunodeficiency Virus

Interventions

Type	Name	Description
DRUG	BMS-663068 (1 tablet at 600 mg)	BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
DRUG	BMS-663068 (4 tablets at 150 mg each tablet)	BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.

Timeline

• Start date: 2016-08-12
• Primary completion: 2016-08-12
• Completion: 2016-08-12
• First posted: 2016-08-09
• Last updated: 2017-05-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study